Axim Biotechnologies Inc (OTCQB:AXIM) issued business highlights for Q3 2017. The company reported that it held bi-annual board meeting in the month of July, during which advisory board and management experts reviewed the firm’s clinical trial development, expanding product portfolio, and stated further proof of concept trials of cannabis based therapy for indications.
Other items noted during the board meeting comprised Axim’s Biotechnologies collaborations with major academic institutions, strategic associations with pharmaceutical distributors and manufacturers for drug development and licensing, and progress on vertical integration with the production facility in Almere. Axim completed production of its second-gen nutraceutical functional chewing gum, named CanChew+® 10 mg with industrial hemp based CBD. It finalized distribution deals for MedChew® Rx and CanChew+® 10 mg with Rafa Pharmaceuticals in Israel.
In the imminent 12-18 months, Axim Biotechnologies intends to accomplish numerous clinical programs. It plans to complete the open-label Phase 2 clinical study with CanChew+®